© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Maviret and Vosevi were highly effective and well tolerated in clinical trials.
The triple-drug combo would be the first once-daily, single-tablet regimen for those with all genotypes who’ve failed a previous treatment.
Gilead has tested the addition of the investigational voxilaprevir to its already approved Epclusa (sofosbuvir/velpatasvir).
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
